Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤Asthma rademikibart improved Day 7 FEV(1) 250 mL versus 120 mL placebo (p=0.023)
- ➤COPD rademikibart cut treatment failure 81% through Week 4 versus placebo (p=0.0122)
- ➤COPD rademikibart reduced new exacerbations 85% through Week 4 versus placebo (p=0.0301)
- ➤FDA discussions planned for potential Phase 3 asthma program in December 2026
- ➤Cash, equivalents and short-term investments totaled $19.5 million at September 30, 2026
Expert Statements
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“Across both studies, rademikibart demonstrated clinically meaningful improvements in outcomes compared to placebo during the high-risk period following an acute exacerbation.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“In asthma patients receiving rademikibart there was a significant improvement in pulmonary function by Day 7 that was maintained through Week 4.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“There were no hospitalizations or emergency department visits through Week 4 in COPD patients receiving rademikibart, which was a 100% reduction compared to placebo.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“We are preparing to engage with the FDA to align on potential pivotal development programs for rademikibart for the treatment of acute asthma exacerbations next month followed by COPD in the first quarter of 2027.”
– Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) –
– Plans to engage with the U.S. Food and Drug Administration (FDA) to gain alignment on potential Phase 3 programs for acute exacerbations of asthma in December 2026 and for COPD in the first quarter of 2027 –
Get started
Create a free account to read the full story.
